Michael Lillestol

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom, Tomas Hala, Michael A. Bolognese et al. · New England Journal of Medicine · 2014 · 713 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity

Louis J. Aronne, Naveed Sattar, Deborah B. Horn et al. · JAMA · 2023 · 709 citations · Full text

Agriculture, Pharmacotherapy, Clinical Pharmacology +16

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi et al. · Diabetes Care · 2019 · 468 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17